Sep 15 2018;14(9):1521-1527
Across these systems, early clinical or translational setbacks were frequently interpreted as evidence of flawed biology rather than limitations in pharmacologic engineering, dosing paradigms, or endpoint selection
Whats perhaps most fascinating, though, is that it has been specifically tested by physicians on patients who are on GLP1s
Patients were randomly assigned to placebo (n=8901) or rosuvastatin 20 mg once daily (n=8901) and were followed for a mean duration of 2 years
These agents are FDA-approved primarily for the management of type 2 diabetes mellitus and, for specific products (Wegovy, Saxenda, Zepbound), for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity
Boeri, L